Clinical Trials Browser

Interventional × von Hippel-Lindau Disease × CNS × Clear all

NCT04924075 2026-05-28

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Phase EARLY_PHASE1 Terminated

CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT01266070 2017-02-13

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Phase 2 Terminated

6 enrolled 5 charts

von Hippel-Lindau Disease, Central Nervous System Neoplasms, Hemangioblastoma